Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...

BAYRY : 6.8000 (+0.44%)
NVS : 109.35 (+0.88%)
REGN : 843.60 (+0.64%)
SNY : 53.27 (+0.74%)
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript

NVS earnings call for the period ending September 30, 2024.

NVS : 109.35 (+0.88%)
3 Absurdly Cheap Stocks That Pay High Dividends

These stocks are trading at less than 15 times their expected future profits.

MRK : 101.88 (-0.43%)
NVS : 109.35 (+0.88%)
GILD : 89.51 (+0.78%)
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

For Immediate ReleaseChicago, IL – October 24, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 111.94 (-0.01%)
NVS : 109.35 (+0.88%)
REGN : 843.60 (+0.64%)
PFE : 28.09 (-0.74%)
BIIB : 173.79 (-0.12%)
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

For Immediate ReleaseChicago, IL – October 23, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 111.94 (-0.01%)
NVS : 109.35 (+0.88%)
REGN : 843.60 (+0.64%)
PFE : 28.09 (-0.74%)
BIIB : 173.79 (-0.12%)
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson reported strong third-quarter results, beating estimates for earnings and sales. J&J consequently...

NVO : 111.94 (-0.01%)
NVS : 109.35 (+0.88%)
REGN : 843.60 (+0.64%)
PFE : 28.09 (-0.74%)
BIIB : 173.79 (-0.12%)
Novartis Gets CHMP Recommendation for Kisqali in Broader Population

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali (ribociclib)...

BAYRY : 6.8000 (+0.44%)
LLY : 818.93 (-1.30%)
NVS : 109.35 (+0.88%)
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move

Novartis is taking a more calculated and strategic approach to its growth.

NVS : 109.35 (+0.88%)
Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU

Bayer BAYRY announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (“EMA”) for its pipeline candidate elinzanetant.The MAA is seeking approval...

BAYRY : 6.8000 (+0.44%)
LLY : 818.93 (-1.30%)
NVS : 109.35 (+0.88%)
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

/CNW/ -- With every October, breast cancer awareness surges thanks to very effective campaigns and new developments in breast cancer treatment. However, this...

ONCY : 1.1800 (+2.61%)
HOLX : 82.33 (+1.81%)
KZIA : 5.52 (+2.22%)
ATOS : 1.4200 (+2.90%)
NVS : 109.35 (+0.88%)
ONC.TO : 1.66 (+4.40%)
KZA.AX : 0.080 (+9.59%)

Barchart Exclusives

The Options Market is Signaling a 22% Spike in Coinbase (COIN). Here’s Your Gameplan.
With the unusual options screener bolstering COIN stock call options, there’s a clever opportunity to set up an intriguing strategy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar